Keywords
How to Cite
Abstract
Introduction: The cardiovascular diseases are the principal cause of death worldwide and a public health problem in Colombia. From the cardiac related illnesses, the most frequent is the Acute Coronary Syndrome (ACS). One of its risk factor is high plasma levels of homocysteine. The enzyme Paraoxonase 1 (PON1) hydrolyzes Homocysteine-thiolactone, producing homocysteine, avoiding damage to endothelium related to Homocysteine-thiolactone. Two genetic variants in PON1 gene have been associated with levels of homocysteine and acute coronary syndrome. Objective: to determine the relationship between the polymorphisms Q192R and L55M from gene PON1 and the levels of homocysteine, HDL, apo A-1 and the enzymatic activity of Paraoxonase I in patients who suffered acute coronary syndrome. Methods: sixteen unrelated patients with Acute Coronary Syndrome (ACS) and sixteen healthy controls were enrolled. The paraoxonase activity, levels of homocysteine, HDL and apo A-1 were assessed. The DNA polymorphism analysis was performed using Polymerase Chain Reaction (PCR) and digestion with restriction enzymes. Results: levels of homocysteine are higher in cases (p<0.0001) and the genotypes 192RR and QR are associated with higher levels of homocysteine (p=0.0234). Conclusion: polymorphisms in PON1 gene could be related to homocysteine levels in Acute Coronary Syndrome patients.
Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, et al. Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Rev Esp Cardiol [internet]. 2012;65(2):173.e1–173.e55. Available from: http://www.revespcardiol.org/contenidos/static/avance_guias/Guia2012_3.pdf.
Ministerio de Salud y Protección Social, Colciencias. Guía práctica clínica para el síndrome coronario agudo [internet]. Bogotá; 2013. Available from: https://www.medicosgeneralescolombianos.com/images/Guias_2013/gpc_17prof_sal_sca.pdf
Secretaría de Salud. Guía de práctica clínica diagnóstico, estratificación y tratamiento de pacientes con síndrome coronario agudo sin elevación ST. México; 2010.
Porth CM. Fisiopatología: salud-enfermedad. Un enfoque conceptual. Bogotá: Editorial Médica Panamericana; 2006.
Rosales M de los AA. Guía para diagnóstico y tratamiento de las personas con síndrome coronario agudo. San José : Editorial Nacional de Salud y Seguridad Social; 2013.
Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J. 2009;30:6-15.
Perła-Kaján J, Jakubowski H. Paraoxonase 1 and homocysteine metabolism. Amino Acids. 2012;43:1405-17.
Companioni O, Rodríguez Esparragón F, Fernández-Aceituno AM, Rodríguez Pérez JC. Genetic variants, cardiovascular risk and genome-wide association studies. Rev Esp Cardiol. 2011;64:509-14.
Bermúdez M, Briceño I, Gil F, Bernal J. Homocisteína y polimorfismos de cistationina β sintasa y metilentetrahidrofolato reductasa en población sana de Colombia. Colomb Med. 37:46-52.
Prieto K, García-Robles R, Bernal J, Bermúdez M. Análisis descriptivo de los niveles de homocisteína, polimorfismos C699T, C1080T y 844Ins68pb de la CBS, C677T de la MTHFR y otros factores de riesgo cardiovascular en una población colombiana con síndrome coronario agudo. Univ Med. 2015;50(4):322-34.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
Instituto Nacional de Salud. Boletín Observatorio Nacional de Salud [internet]. 2013 dic 9;(1). Disponible en: http://www.ins.gov.co/lineas-de-accion/ons/boletin%201/boletin_web_ONS/boletin_01_ONS.pdf
Santilli F, Davì G, Patrono C. Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective. Vascul. Pharmacol. 2016;78:1-9.
Bawaskar HS, Bawaskar P himmatrao, Bawaskar PH. Homocysteine and cardiovascular system. Int Res J Pharm Sci. 2015;1-7.
Kresanov P, Vasankari T, Ahotupa M, Kaikkonen J, Hutri-Kähönen N, Juonala M, et al. Paraoxonase-1 and oxidized lipoprotein lipids: The cardiovascular risk in young finns study. Atherosclerosis. 2015;241:502-6.
Koubaa N, Nakbi A, Hammami S, Attia N, Mehri S, Ben Hamda K, et al. Association of homocysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome. Clin Biochem. 2009;42:771-6.
Gugliucci A, Menini T. Paraoxonase 1 and HDL maturation. Clin Chim Acta. 2015;439:5-13.
Kallel A, Sediri Y, Sbaï MH, Mourali MS, Feki M, Elasmi M, et al. The paraoxonase L55M and Q192R gene polymorphisms and myocardial infarction in a Tunisian population. Clin Biochem. 2010;43:1461-3.
Lakshmy R, Ahmad D, Abraham RA, Sharma M, Vemparala K, Das S, et al. Paraoxonase gene Q192R & L55M polymorphisms in Indians with acute myocardial infarction & association with oxidized low density lipoprotein. Indian J Med Res. 2010;131:522-9.
Wang M, Lang X, Zou L, Huang S, Xu Z. Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: A meta-analysis based on 88 case-control studies. Atherosclerosis. 2011;214:377-85.
Regieli JJ, Jukema JW, Doevendans PA, Zwinderman AH, Kastelein JJ, Grobbee DE, et al. Paraoxonase variants relate to 10-year risk in coronary artery disease: Impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J. Am. Coll. Cardiol. J Am Colleg Cardiol. 2009;54:1238-45.
Roever L, Reis P. Screening for peripheral arterial disease: An update. J Vasc Med Surg [internet]. 2015;3:197. Available from: https://www.esciencecentral.org/journals/screening-for-peripheral-arterial-disease-an-update-2329-6925-1000197.php?aid=54124
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.